Sagimet Biosciences (SGMT) Net Cash Flow (2022 - 2026)

Sagimet Biosciences' Net Cash Flow history runs 5 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 114.43% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was -$28.1 million, a 74.93% increase from a year earlier, with the FY2025 full-year figure at -$40.8 million, down 5922.97% from the prior year.
• Net Cash Flow fell to $1.6 million in Q1 2026 per SGMT's latest filing, from $2.5 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $101.6 million in Q1 2024 and bottomed at -$80.8 million in Q2 2024.
• The 5-year median for Net Cash Flow is -$1.6 million (2022), against an average of $2.0 million.
• Across the five-year window, Net Cash Flow soared 205766.67% in 2023 and tumbled 1409.85% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$2.1 million in 2022, then slumped by 1188.75% to -$26.7 million in 2023, then surged by 95.6% to -$1.2 million in 2024, then surged by 315.08% to $2.5 million in 2025, then sank by 36.44% to $1.6 million in 2026.
• Per Business Quant, the three latest SGMT Net Cash Flow figures stand at $1.6 million (Q1 2026), $2.5 million (Q4 2025), and -$9.8 million (Q3 2025).